

**ALLEGED SHIPMENT:** September 15 and 20 and October 19 and 26, 1946, by B. Ostroff, from Pittsburgh, Pa.

**PRODUCT:** 4 55-gallon barrels of *Ramol* at Cleveland, Ohio. Analysis showed that the product was United States Pharmacopoeia Mineral Oil.

**LABEL, IN PART:** "Ramol 350 Oil U. S. P."

**NATURE OF CHARGE:** Misbranding, Section 502 (e) (1), the article was not designated solely by a name recognized in an official compendium, and its label failed to bear the common or usual name of the drug, mineral oil.

**DISPOSITION:** March 6 and April 1, 1947. No claimant having appeared, judgments of condemnation were entered and the product was ordered destroyed.

### DRUG ACTIONABLE BECAUSE OF FAILURE TO BEAR AN ACCURATE STATEMENT OF THE QUANTITY OF THE CONTENTS\*

**2200. Misbranding of Sulfa-Tyro-Cide. U. S. v. Oliver W. Nelson (Nelson Laboratories). Plea of guilty. Fine, \$50. (F. D. C. No. 21462. Sample No. 51522-H.)**

**INFORMATION FILED:** April 16, 1947, District of South Dakota, against Oliver W. Nelson, trading as Nelson Laboratories, at Sioux Falls, S. Dak.

**ALLEGED SHIPMENT:** On or about April 29, 1946, from the State of South Dakota into the State of Minnesota.

**PRODUCT:** Analysis showed that the product contained sulfanilamide, sulfathiazole, and ammonium chloride.

**LABEL, IN PART:** "Sulfa-Tyro-Cide."

**NATURE OF CHARGE:** Misbranding, Section 502 (b) (1), the article failed to bear a label containing the place of business of the manufacturer, packer, or distributor; and, Section 502 (b) (2), the label failed to contain an accurate statement of the quantity of the contents since the bottle label contained no statement of the quantity of the contents.

**DISPOSITION:** April 30, 1947. The defendant having entered a plea of guilty, the court imposed a fine of \$50.

### INDEX TO NOTICES OF JUDGMENT D. D. N. J. NOS. 2151 TO 2200

#### PRODUCTS

	N. J. No.		N. J. No.
Acidoflacc-----	2177	F Y A Tablets-----	2156
Amphetamine sulfate tablets_	2153, 2154	Far-Vet Merco-Tabs, Far-Vet	
Apiphene-----	2179	Gwyo-Dine Tablets, and Far-	
Atabrine tablets-----	2153, 2154	Vet Gwyo-Spray-----	2190
B Complex Ironated tablets-----	2181	Ferrolene Tablets-----	2156
Blake's Mineral Compound-----	2194	First aid kits-----	2153, 2154
Bonquet Tablets-----	2180	Foot remedies-----	2172, 2173
Charcoal, medicated-----	2189	Gemocco-----	2192
Clark's, Dr., Udder Salve-----	2187	General Hog Liquid-----	2188
Corn King Udder Ointment-----	2187	Guardex-----	2193
Cosmetics (subject to the drug		Hair and scalp preparations_	2167, 2184
provisions of the Act) --	2167, 2184	Hi-A Vitamin capsules-----	2181
Dencol-10-----	2186	Histamine acid phosphate-----	2162
Devices-----	2157, 2168, 2185	Ideal Livestock and Poultry Liq-	
Devonshire's Earth Salts_	2170, 2171	uid-----	2195
Diathermy machines-----	2157	Injection preparations. See Pa-	
Dicalcium Phosphate Wafers		renteral drugs.	
with Viosterol-----	2181	Iodine, tincture of-----	2153, 2154
Diet Tablets-----	2161	Jaques' Poultry Preparation,	
Digitalis tablets-----	2160	Jaques' Worm Powder,	
Dwarfies 10-Vitamin Tablets-----	2159	Jaques' B C R, and Jaques'	
Early Bird worm medicine-----	2196	Inhalant Spray-----	2191
Estrogenic substances-----	2169		

\*See also No. 2198.

<sup>1</sup> (2171) Prosecution contested.

# FEDERAL SECURITY AGENCY

## FOOD AND DRUG ADMINISTRATION

### NOTICES OF JUDGMENT UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT

[Given pursuant to section 705 of the Food, Drug, and Cosmetic Act]

2201-2250

#### DRUGS AND DEVICES

The cases reported herewith were instituted in the United States district courts by the United States attorneys acting upon reports submitted by direction of the Federal Security Administrator.

OSCAR R. EWING, *Administrator, Federal Security Agency.*

WASHINGTON, D. C., *January 6, 1948.*

#### CONTENTS \*

	Page		Page
Drugs actionable because of failure to bear adequate directions or warning statements.....	403	Drugs and devices actionable because of false and misleading claims.....	410
Drugs actionable because of contamination with filth.....	404	Drugs for human use.....	410
Drugs and devices actionable because of deviation from official or own standards.....	405	Drugs for veterinary use.....	419
		Index.....	425

#### DRUGS ACTIONABLE BECAUSE OF FAILURE TO BEAR ADEQUATE DIRECTIONS OR WARNING STATEMENTS

**2201. Misbranding of seconal sodium pulvules. U. S. v. Dayton B. Blaine and Claude C. Schwab. Pleas of guilty. Defendants fined \$500 and \$100, respectively. (F. D. C. No. 21453. Sample Nos. 24032-H, 49052-H, 49162-H.)**

**INFORMATION FILED:** March 11, 1947, Northern District of Texas, against Dayton B. Blaine and Claude C. Schwab, president and manager, respectively, of the Red Cross Pharmacy, Inc., Dallas, Tex.

**INTERSTATE SHIPMENT:** Between the approximate dates of January 14 and 30, 1946, from Indianapolis, Ind.

**LABEL, IN PART (When shipped):** "Pulverized Seconal Sodium 1½ Grs. (0.1 Gm.) (Sodium Propyl-methyl-carbinyl Allyl Barbiturate, Lilly) \* \* \* Caution—to be dispensed only by or on the prescription of a physician."

**NATURE OF CHARGE:** That on or about April 3, 4, and 7, 1946, while a number of capsules of the drug were being held for sale after shipment in interstate commerce, the defendants caused to be removed a number of the capsules from the bottle in which they were shipped, caused to be repacked the aforesaid capsules into envelopes which were unlabeled except for the figure "12" which appeared on several of the envelopes, and caused to be sold these capsules without a prescription.

The information charged further that the acts of the defendants resulted in the misbranding of the drug in the following respects: Section 502 (d), the drug contained a chemical derivative of barbituric acid, which derivative has been found to be, and by regulations designated as, habit-forming, and the label

\*For presence of a habit-forming narcotic without warning statement, see No. 2201; omission of, or unsatisfactory, ingredients statements, Nos. 2223, 2234, 2240, 2243; failure to comply with the packaging requirements of an official compendium, No. 2214; failure to bear a label containing an accurate statement of the quantity of the contents, Nos. 2221, 2232, 2234, 2240, 2243; failure to bear a label containing the name and place of business of the manufacturer, packer, or distributor, No. 2240; cosmetics, subject to the drug provisions of the Act, Nos. 2230-2234.